The biotech sector has a reason for hope in 2026. Venture capital has returned to the market after a long period of caution. More money is back in the sector, public markets look healthier, and large deals have become more common. Yet this recovery does not reach every biotech firm in the same way.
Young startups face a much harder path to new capital. A new report from Massachusetts shows a sharp gap between seed deals and Series A deals. The wider venture market may look better, but the first steps for a new biotech company remain difficult.
This gap matters because biotech starts with high risk. A new company can have a strong idea, good science and a clear medical need, yet still have no clinical proof. Investors now seem more willing to back firms that have already passed some of these early tests. That leaves very young firms with fewer options.
The Massachusetts numbers tell the story
The Massachusetts biotech market offers a useful view of this shift. Biopharma companies in the state raised $3.45 billion in venture capital in the first half of 2026, a 25% rise from the same period a year earlier.
At first glance, that looks like a strong recovery. But the details show a very different picture for young firms.
The average seed round fell to $4.65 million. At the same time, the average Series A round rose to $79.6 million. The gap between those two stages is striking. A Series A deal now carries far more capital than a typical seed deal.
That does not mean every Series A company gets $79.6 million, nor does it mean every seed company gets only $4.65 million. These are average figures. Still, the change shows where investors are more comfortable with risk.
The wider US biotech market tells a similar story. Biotech companies raised $4.4 billion through seed and Series A rounds in the first half of 2026. That was 15% below the same period in 2025 and 47% below the first-half peak in 2021.
Fewer young companies get a chance
The number of early-stage deals may be an even bigger concern than the total amount of cash.
In the first half of 2026, the number of disclosed seed and Series A biotech deals fell to 142, the lowest first-half total in a decade. That was 53% below the 2021 peak.
This creates an unusual situation. The market has a large pool of capital, but that money does not reach as many new companies as it did during the stronger years of the biotech boom.
In simple terms, more money can go to fewer firms.
That matters because a biotech startup needs several rounds of capital before it can become a mature company. Seed money can help a team test its first idea, build a small research group and create early data. Series A capital can then support a larger research plan and help a company move closer to human trials.
If the first step becomes harder, fewer companies may reach the second step.
Why investors prefer later-stage biotech
The main reason is risk.
A very young biotech company often has little more than an idea, early lab data or a new technology. There may be no human data. There may also be no clear proof that the science will work in patients.
For investors, this creates a long list of unknowns. A drug can fail because it does not work, causes safety problems or cannot reach its target. Even a strong scientific idea can face years of tests before it becomes a real treatment.
A company with a clinical asset offers more evidence. It may have data from human trials, a clearer path to the next milestone and a better idea of how much money it needs. That can make the risk easier to assess.
BioCentury reports that about two-thirds of venture dollars in the first half of 2026 went to companies that already had a drug candidate in human testing.
That figure helps explain the gap. Investors have not left biotech. They have become more selective about where they place their money.
Big deals make the recovery look stronger
Another factor is the rise of very large rounds.
In the first half of 2026, 14 biotech rounds of $200 million or more accounted for $6.1 billion in capital. That was close to one-third of all biotech venture capital for the period.
Such deals can lift the total market number very fast. They also show that investors still have the ability to write very large checks when they see a company with strong data or a valuable asset.
But a $200 million deal for one company does little for dozens of small startups that need a few million dollars to reach their next scientific milestone.
This is why the headline total can give the wrong impression. A market can have more capital while the average young founder still finds it hard to raise enough money.
What this means for biotech founders
For founders, the message is clear. A good idea may no longer be enough to secure a large seed or Series A round.
Investors may want stronger proof before they commit serious capital. That can include clear lab results, strong evidence of a drug target, early safety data or a plan that shows how the company can reach a major value point with a modest amount of cash.
This puts more pressure on founders to use each dollar with care. Teams may need to reach a key scientific milestone before they ask for a larger round.
It can also change company strategy. Some founders may choose to work with universities, research groups or large drug companies before they form a full startup. Others may seek grants or other non-dilutive capital as a way to extend their runway.
The goal is simple: survive long enough to create the data that later investors want to see.
A concern for future biotech innovation
The issue goes beyond individual startups.
Biotech depends on a steady flow of new ideas. Some will fail. That is normal. A few, however, can become major drugs or new platforms that change how diseases get treated.
If fewer young companies receive early capital, fewer ideas may get the chance to prove themselves.
That could create a problem several years from now. Today’s investors may have strong returns from mature biotech assets, but the sector also needs new companies to replace those assets.
The risk is not an immediate collapse in biotech venture capital. The $4.4 billion raised through seed and Series A deals in the first half of 2026 was close to levels seen in the first halves of 2019, 2020 and 2024, and more than twice the $2.1 billion seen in the first half of 2017.
The bigger issue is the number of companies that receive that money.
The next test for the market
The biotech sector now faces an important test. Can the wider venture recovery reach the earliest part of the market, or will capital remain focused on firms with clinical proof?
Massachusetts offers a strong example of both sides of the story. The state has seen $3.45 billion in venture capital in the first half of 2026, a 25% annual rise. Yet the average seed round has fallen to $4.65 million, while the average Series A has reached $79.6 million.
That is not a simple boom or bust story. It is a story of selective confidence.
Investors appear ready to place large sums behind biotech firms that have reduced some of the scientific risk. Young startups, however, still have to cross a much harder first hurdle.
For the biotech sector, that gap may prove more important than the headline recovery itself. A healthy market needs strong companies at every stage, from the first scientific idea to the final clinical trial. If the flow of capital stops too early, today’s recovery could leave tomorrow’s biotech pipeline much thinner than expected.
ALSO READ: Volve Raises $3M to Bring AI to Construction Tendering